BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/30/2026 1:40:17 PM | Browse: 0 | Download: 0
 |
Received |
|
2025-12-22 03:07 |
|
Peer-Review Started |
|
2025-12-22 03:07 |
|
First Decision by Editorial Office Director |
|
2026-01-20 09:27 |
|
Return for Revision |
|
2026-01-20 09:27 |
|
Revised |
|
2026-01-30 05:43 |
|
Publication Fee Transferred |
|
2026-02-03 03:29 |
|
Second Decision by Editor |
|
2026-03-23 02:44 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-23 08:27 |
|
Articles in Press |
|
2026-03-23 08:27 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-16 00:25 |
|
Publish the Manuscript Online |
|
2026-06-30 13:40 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Radiotherapy-free neoadjuvant strategy using sintilimab plus XELOX in locally advanced rectal cancer: A single-arm phase II trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wei-Dong Qiang, Qi Wei, Bo Yang, Wan-Jing Chen, Chang-Qing Lin and Yong-Xiang Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82372646 |
|
| Corresponding Author |
Yong-Xiang Li, PhD, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Hefei 230022, Anhui Province, China. liyongxiang@ahmu.edu.cn |
| Key Words |
Locally advanced rectal cancer; Immunotherapy; Sintilimab; Radiotherapy-free; Pathological complete response |
| Core Tip |
This phase II single-arm study evaluated a radiotherapy-free neoadjuvant strategy using sintilimab plus XELOX in patients with locally advanced rectal cancer without mesorectal fascia involvement. The regimen achieved favorable pathological responses with acceptable toxicity. Tumor size > 4 cm and elevated baseline carcinoembryonic antigen levels were associated with a lower likelihood of major pathological response. Exploratory immune microenvironment analysis suggested a potential association between CD8+ T-cell infiltration and treatment response. These findings support further investigation of radiotherapy-sparing strategies in carefully selected patients. |
| Publish Date |
2026-06-30 13:40 |
| Citation |
Qiang WD, Wei Q, Yang B, Chen WJ, Lin CQ, Li YX. Radiotherapy-free neoadjuvant strategy using sintilimab plus XELOX in locally advanced rectal cancer: A single-arm phase II trial. World J Gastroenterol 2026; 32(26): 117924
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i26/117924.htm |
| DOI |
https://doi.org/10.3748/wjg.117924 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
